BeyondSpring

$11.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (+2.75%) Today
-$0.09 (-0.80%) As of 12:04 PM UTC after-hours

Why Robinhood?

You can buy or sell BeyondSpring and other stocks, options, and ETFs commission-free!

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY. The listed name for BYSI is BeyondSpring Inc. Ordinary Shares.

CEO
Lan Huang
Employees
61
Headquarters
New York, New York
Founded
2013
Market Cap
341.48M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.14M
High Today
$11.35
Low Today
$10.70
Open Price
$11.12
Volume
687.81K
52 Week High
$21.50
52 Week Low
$9.38

Collections

BYSI Earnings

-$0.64
-$0.43
-$0.21
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.48 per share

You May Also Like